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  Angiotensin-I converting enzyme (ACE) is a key regulator 
of  blood  pressure,  electrolytes  and  fluid  homeostasis 
through  conversion  of  angiotensin  I  into  angiotensin  II. 
Recently, a genetic polymorphism of the ACE gene, which 
accounts  for  47%  of  the  variation  of  ACE  activity  in 
blood,  has  been  advocated  as  a  biomarker  of  athletic 
aptitude. Different methods of analysis and determination 
of ACE activity in plasma have been used in human and 
equine research without a consensus of a “gold standard” 
method.  Different  methods  have  often  been  used 
interchangeably  or  cited  as  being  comparable  in  the 
existing literature; however, the actual agreement between 
assays has not been investigated. Therefore, in this study, 
we  evaluated  the  level  of  agreement  between  three 
different  assays  using  equine  plasma  obtained  from  29 
horses. Two spectrophotometric assays using Furylacryloyl- 
phenylalanyl-glycyl-glycine as substrate and one fluorimetric 
assay  utilizing  o-aminobenzoic  acid-FRK-(Dnp)P-OH 
were employed. The results revealed that the measurements 
from the different assays were not in agreement, indicating 
that the methods should not be used interchangeably for 
measurement  of  equine  ACE  activity.  Rather,  a  single 
method of analysis should be adopted to achieve comparable 
results  and  critical  appraisal  of  the  literature  is  needed 
when  attempting  to  compare  results  obtained  from 
different assays.
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Introduction 
Angiotensin I-converting enzyme (ACE) is responsible 
for the conversion of angiotensin I into angiotensin II and 
therefore plays a major role in blood pressure regulation 
and fluid and electrolyte homeostasis. ACE activity 
measurement in blood samples is a useful tool in human 
medicine for the detection and treatment monitoring of 
diseases such as sarcoidosis and hypertension. In small 
animal veterinary medicine, blood ACE is used to monitor 
hypertension and heart failure [4]. In horses, elevated 
blood ACE levels have been found to be associated with 
endometrial disease [15], gestational stage [23] and 
laminitis [16]. ACE levels in blood obtained from human 
athletes have been correlated with a genetic polymorphism 
and aptitude for endurance sports [19,21]. This 
polymorphism accounts for almost 50% of the variation in 
ACE activity in plasma [25,30]. Similar genetic 
polymorphisms have been identified in horses [12], and 
research results have demonstrated an inverse correlation 
between ACE activity in the blood and the distance 
successfully raced by Thoroughbred racehorses [10]. 
These recent developments warranted further investigation 
to test whether ACE activity in equine blood could be used 
as a marker of performance and fitness, and therefore an 
assessment of the agreement between existing ACE assays 
for use in horses was relevant. Several methods for 
measuring ACE in plasma and serum samples have been 
described for human beings. Some of these, which employ 
substrates such as hippuryl-histidyl-leucine (HHL) [14,20] 
and 
3H-hippuryl-glycyl-glycine [29] and use a change in 
ultraviolet absorbance to measure the kinetics [16], have 
previously been described for use in equine serum or 
plasma. Recently, Alves et al. [1] validated the use of the 
fluorescence resonance energy transfer (FRET) substrate 
o-aminobenzoic acid-FRK(Dnp)P-OH (referred to as 
ABZ) [2] for assaying human ACE levels and established 
that there is a good correlation between a 
spectrophotometric method employing HHL as the 
substrate and the fluorimetric method using the ABZ 
substrate in humans [1,27]. Other methods and their 22    Maria Fernanda de M. Costa et al.
applications can be found in the literature [1,3,11,14,17, 
20,22,24,28,29]. The objective of this study was not to 
validate the methods used for equine samples, since that 
has been done previously. Rather, this study was conducted 
to determine whether the results obtained using different 
methods were comparable and to assess the level of 
agreement between methods for measuring ACE activity 
in equine plasma. To accomplish this, we compared three 
different assays previously utilized in human research. 
Materials and Methods
Experimental animals
The population studied comprised 29 horses, of which 26 
(90%) were Thoroughbreds, two (7%) were mixed breeds 
and one (3%) was a Standardbred. The ages of the horses 
ranged from 3 to 16 years and there were 16 males (13 
geldings and 3 colts) and 13 females. Blood samples (10 
mL per horse) were collected between 7 AM and 10 AM by 
simple venipuncture from one of the jugular veins into 
heparinized vacuum tubes. The blood was immediately 
placed and then kept on ice and promptly centrifuged at 
3,400 × g for 10 min in a refrigerated centrifuge (GS15R; 
Beckman, Australia) at 4
oC. The resulting plasma was 
harvested and transferred with sterile disposable plastic 
pipettes in aliquots into labeled microtubes (Eppendorf, 
Australia). The sample aliquots were snap-frozen in liquid 
nitrogen and stored in a −70
oC freezer until analysis. Each 
aliquot was used once, after a single cycle of thawing. 
Sample aliquots were not thawed and refrozen. From 
collection to freezing, the process took a maximum of 2 h.
ACE Infinity (ACEIn) method (method 1)
This method utilized kinetic spectrophotometry and a 
commercially available assay kit, ACE Infinity (Thermo- 
Fisher, USA), developed for ACE measurement in both 
plasma and serum. This assay is based on the chemical 
reaction between ACE and the substrate furylacryloyl- 
phenylalanyl-glycyl-glycine (FAPGG), which causes a 
decrease in absorbance at 340 nm. The method employs a 
ready-to-use calibrator and substrate reagents and uses 30 
μL of plasma and 300 μL of substrate for each sample 
analyzed. The linearity of the assay is between 1 and 120 
U/L and the sensitivity is described by the manufacturer as 
0.084ΔmA/min per U/L. Calibration methodology for the 
spectrophotometer is provided by the kit manufacturer. 
Furylacryloyl-phenylalanyl-glycyl-glycine (FAPGG) 
method (method 2)
This method is also a kinetic spectrophotometric method 
based on the chemical reaction between ACE and FAPGG 
(F7131; Sigma-Aldrich, Australia). The method utilizes 
raw chemicals instead of a pre-assembled assay kit. 
Samples must be run with both blanks and substrate 
reagent. The method also requires preparation of an 
HEPES buffer. The analytical range for ACE activity 
varies from 5∼200 U/L. Hydrolysis of the substrate 
causes a decrease in absorbance at 340 nm. The complete 
description of the method has been published elsewhere 
[5,26]. Methods 1 and 2 require a 5 min incubation period 
at 37
oC and the results are given in U/L (based on the fact 
that 1 unit of ACE converts 1 μmol of FAPGG/min at 
37
oC).
o-aminobenzoic acid-FRK(Dnp)P-OH (ABZ) method 
(method 3)
This method uses the FRET substrate Abz-FRK(Dnp)P- 
OH (A4980; Sigma-Aldrich, Australia) and requires 
calibration of the fluorimeter with respect to the 
concentration of Abz-FRK(Dnp)P-OH to guarantee 10 μM 
of substrate in each sample analysed. We used a 
fluorimeter (Cary Varian, Australia) with chamber 
temperature control and constant magnetic stirring. This 
method provides real time kinetic readings of enzyme 
activity utilizing wavelengths of 320 nm (excitation) and 
420 nm (emission). The results are given in arbitrary 
fluorescent units and have to be converted into U/L by 
finding the conversion constant of the equipment through 
complete hydrolysis of the substrate by a known 
concentration of commercially available enzyme in pure 
form, rabbit lung enzyme (A6778; Sigma-Aldrich, 
Australia). The complete method has been described 
elsewhere [1,8,27]. We used the average of readings taken 
for 310 sec for comparison with the ACEIn and FAPGG 
method. To evaluate the precision of the methods, 
repeatability studies were conducted in 33 samples 
obtained specifically for this purpose. Collection and 
processing were similar to that for the samples used in the 
agreement study. The analytical coefficient of variation 
(CV), within-run (CVw), and between-run (CVb) 
coefficients of variation were calculated using ANOVA 
and the “between/within” capability of the statistical 
software (Minitab 15.1.30.0; Minitab, USA). The sensitivity 
of each substrate was established based on the Kcat/Km 
values found in the literature [7,8]. The results from the 
different methods were compared using the Bland and 
Altman method [6,18] to determine the limits of agreement 
and confidence intervals as per the MedCalc v11.3.0 
software (MedCalc, Belgium) and WinPepi v10.5 software 
(Brixton Health, UK). Acceptable agreement was considered 
to have occurred when two ACE measurements derived 
from two methods were within 5 to 10 U/L of each other in 
95% of the occasions. This was based on the mean value 
obtained from each method, and represents a difference of 
10% of the mean. Coefficients of determination (r
2) were 
calculated to investigate linearity and association. 
Statistical significance of a quadratic coefficient was also 
assessed.Agreement of methods for equine ACE    23
Fig. 1. Bland and Altman plot showing the limits of agreement 
(two outer lines), 95% confidence interval of the mean difference
(two lines on either side of the mean) and the mean difference 
between the furylacryloyl-phenylalanyl-glycyl-glycine (FAPGG)
method and the angiotensin I-converting enzyme Infinity 
(ACEIn) method. n = 29.
Fig. 3. Bland and Altman plot showing the limits of agreement 
(two outer lines), 95% confidence interval of the mean difference
(two lines on either side of the mean) and the mean difference 
between the o-aminobenzoic acid-FRK(Dnp)P-OH (ABZ) method
and angiotensin I-converting enzyme Infinity (ACEIn) method. 
n = 29.
Fig. 2. Bland and Altman plot showing the limits of agreement 
(two outer lines), 95% confidence interval of the mean difference
(two lines on either side of the mean) and the mean difference 
between the furylacryloyl-phenylalanyl-glycyl-glycine (FAPGG)
method and the o-aminobenzoic acid-FRK(Dnp)P-OH (ABZ) 
method. n = 29.
Results
The mean ± SD of 29 samples was 69.0 ± 16.5 U/L for the 
ACEIn method, 89.8 ± 19.5 U/L for FAPGG method and 
85.1 ± 24.8 U/L for the ABZ method. The CV for each 
method was 4.3% for the ACEIn method, 2.8% for the 
FAPGG method and 13.6% for the ABZ method. The 
respective CVw and CVb values were 2.7% and 10.1% for 
the ACEIn method, 2.5% and 14.5% for the FAPGG 
method and 9.5% and 14.8% for the ABZ method. 
Complete ACE activity inhibition was achieved in the 
ABZ method by adding captopril to the samples before 
analysis. Ninety eight percent of the ACE activity was 
inhibited by EDTA in the ACEIn method, while 97.7% was 
inhibited in the FAPGG method. The results (Figs. 1-3) 
showed that measurements of ACE acquired by different 
methods had poor agreement. For the FAPGG method and 
ACEIn method, the lower limit of agreement was −8.4 
(95%CI  −18.2 to 1.4 U/L) and the upper limit of 
agreement was 49.9 (95%CI 40.2 to 59.7 U/L). For the 
FAPGG method and ABZ method, the lower limit of 
agreement was −28.8 (95%CI −40.1 to −17.6 U/L) and 
the upper limit of agreement was 38.3 (95%CI 27.0 to 49.6 
U/L). Finally, for the ABZ method and the ACEIn method, 
the lower limit of agreement was −26.3 (95%CI −40.6 to 
−12.1 U/L) and the upper limit of agreement was 58.4 
(95%CI 44.2 to 72.6 U/L). The correlation between the 
difference and average was 0.23 (p = 0.24) for the FAPGG 
and ACEIn methods, −0.33 (p = 0.08) for the FAPGG and 
ABZ methods, and 0.44 (p = 0.02) for the ABZ and ACEIn 
methods. Removal of the observation with the greatest 
difference between the ABZ method and ACEIn method 
(difference of 67.6) resulted in the correlation between the 
difference and average being 0.34 (p = 0.08). Coefficients 
of determination were 0.45 between the ACEIn method 
and FAPGG method, 0.26 between the ABZ method and 
ACEIn method and 0.53 between the ABZ method and 
FAPGG method. None of the non-linear quadratic 
coefficients were significant (p values ＞ 0.75). 
Discussion
In the past, measurements obtained from different methods 
in horses were compared [9,20,29] with conclusions being 
drawn partially based on these results. Normality ranges 24    Maria Fernanda de M. Costa et al.
obtained by one method [29] were assumed to be valid for 
other methods, and established as reference values. 
However, in humans, it has been demonstrated that the 
high intra-individual variation of ACE activity in blood 
precludes the use of a single reference interval for 
determination of normality [13]. Furthermore, as is the 
case with biological products such as enzymes, each 
method produces its own reference ranges within a wider 
populational normality range. Therefore, it seems 
inappropriate to cross-utilize values obtained by one 
methodology as references for all methods. This study 
demonstrated that there is poor agreement between 
different methods of analysis of equine ACE activity in 
plasma; therefore, these methods should not be used 
interchangeably. Variation in the mean value of ACE 
observed with different methods is likely to come from the 
fact that different protocols (spectrophotometric and 
fluorimetric) and different substrates (ACEIn and FAPGG 
vs. ABZ) were used. Nevertheless, a degree of comparability 
between methods was expected. Judicious analysis of 
literature utilizing ACE results obtained from one method 
but utilizing ACE reference values obtained from a second 
method is necessary. Previous studies on how to determine 
method agreement for clinical measures have been 
published and we have followed those guidelines [6,18]. 
We propose that comparison between results for equine 
ACE activity obtained from different methods should not 
be attempted, since this may be misleading. In conclusion, 
the results of this study demonstrate that different assays 
have poor agreement and should not be used 
interchangeably. Accordingly, linear regression should not 
be used to establish a transformation equation to compare 
results from different methods, even for clinical purposes. 
In terms of the precision of each method, the FAPGG 
method and ACEIn method showed the lowest analytical 
CV and within-run variation, while the ACEIn method had 
the lowest between-run coefficient of variation. Overall, 
the results presented here indicate that it is critical to 
adhere to a single method of analysis to achieve 
comparability of samples.
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